Callahan Advisors LLC Has $21.70 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 2nd, 2023

Callahan Advisors LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 122,836 shares of the company’s stock after purchasing an additional 1,398 shares during the quarter. Johnson & Johnson comprises 3.0% of Callahan Advisors LLC’s holdings, making the stock its 5th biggest position. Callahan Advisors LLC’s holdings in Johnson & Johnson were worth $21,699,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Veracity Capital LLC grew its holdings in shares of Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after purchasing an additional 59 shares in the last quarter. Sandy Cove Advisors LLC grew its holdings in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after purchasing an additional 60 shares in the last quarter. LCM Capital Management Inc grew its holdings in shares of Johnson & Johnson by 0.7% during the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after purchasing an additional 61 shares in the last quarter. Arbor Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 2.3% during the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after purchasing an additional 61 shares in the last quarter. Finally, Mason & Associates Inc grew its holdings in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after purchasing an additional 62 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Raymond James reduced their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. StockNews.com started coverage on Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. UBS Group started coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Finally, SVB Leerink lowered their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $173.00.

Johnson & Johnson Stock Down 0.1 %

JNJ stock opened at $163.60 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The company has a market capitalization of $426.06 billion, a price-to-earnings ratio of 34.23, a PEG ratio of 2.78 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The stock has a fifty day moving average of $157.86 and a 200-day moving average of $167.04.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.67 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 2.91%. Johnson & Johnson’s dividend payout ratio is presently 94.56%.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.